alexa The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus.

Journal of Autacoids and Hormones

Author(s): BorchJohnsen K, Andersen PK, Deckert T

Abstract Share this page

Abstract We followed 1,134 patients with Type 1 (insulin-dependent) diabetes, diagnosed between 1933 and 1952, until 1982 or death or until their emigration. Their age at onset of diabetes was under 31 years. Information concerning the development of persistent proteinuria was sought in every case. In 104 cases, the data were either questionable or the patient could not be traced. Twenty-nine patients developed non-diabetic proteinuria. Among the remaining 1,001 patients, 406 developed persistent proteinuria (350 died) and 595 did not (166 died). The incidence of persistent proteinuria was highest among men; it decreased with increasing year of diabetes onset from 1933 to 1952, and decreased with increasing age at onset. The relative mortality was extremely high among patients with persistent proteinuria, increasing to a maximum of about 100 at age 35 years. Patients not developing proteinuria had a relatively constant low relative mortality of about 2. The decreasing incidence of persistent proteinuria and the decreasing mortality with increasing calendar year of diabetes onset resulted in a 50\% increase in life-expectancy among patients diagnosed in 1950 compared with patients diagnosed in 1935. In patients who developed persistent proteinuria, relative mortality was higher in women than men at all ages. In patients who did not develop proteinuria, relative mortality was similar in men and women after the age of 35. Uraemia was the main cause of death in patients with persistent proteinuria, although cardiovascular deaths were more frequent than in patients without proteinuria. Thus, proteinuria is associated not only with death from uraemia but also from cardiovascular disease.(ABSTRACT TRUNCATED AT 250 WORDS)
This article was published in Diabetologia and referenced in Journal of Autacoids and Hormones

Relevant Expert PPTs

Relevant Speaker PPTs

  • Rasha Mosa
    Effects of growth hormone secretagogue receptor agonist and antagonist in non-obese Type 2 Diabetes MKR mice
    PPT Version | PDF Version
  • Nisreen K Aref
    To compare serum leptin levels in obese women with polycystic ovary syndrome (PCOS) and normal ovulatory obese subjects in Saudi Arabia, and to evaluate the interrelationship between leptin concentration, sex hormones, and insulin resistance.
    PPT Version | PDF Version
  • George R. Bousfield
    Influence of Glycans on Biological Activities of Pituitary Gonadotropins: Follicle-Stimulating and Luteinizing Hormone
    PPT Version | PDF Version
  • P Krishnamoorthy
    Relationship of mineral and hormone profile of bovines with reproductive disorders in organized dairy farms in Karnataka and Tamil Nadu
    PPT Version | PDF Version
  • John Arnold D Souza
    Low levels of pesticides disrupt the pituitary- Gonadal hormone functions and reproductive functions in male rodent model
    PPT Version | PDF Version
  • Martha M Sklavos
    Anti-Müllerian hormone deficiency in females with inherited bone marrow failure syndromes
    PDF Version
  • Fuad Fares
    Developing long acting agonists and antagonists of glycoprotein hormones using gene fusion and gene transfer: From bench to clinics
    PPT Version | PDF Version
  • Paul J. Davis
    Nanotetrac targets the thyroid hormone receptor on integrin αvβ3 on tumor cells to promote apoptosis, disorder cell defense pathways and block angiogenesis
    PPT Version | PDF Version
  • A Martin Gerdes
    Wrong about β-blockers! Wrong about positive inotropes! Wrong about Thyroid Hormone treatment of Heart Failure?
    PDF Version

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version